Strengths

Liquidity is strong versus distressed microcap peers, with current and quick ratios of 5.9x, reducing near-term funding pressure despite weak operating performance.

Debt-to-equity is reported at zero, which compares favorably with leveraged peers and limits balance-sheet fragility from explicit financial leverage.

The company’s capital structure appears less encumbered than many small-cap biotech peers, supporting optionality if operating execution improves over the next 2–5 years.

Weaknesses

Return on invested capital is deeply negative at -92.9%, indicating capital destruction that is materially worse than profitable peers and undermines structural competitiveness.

The cash conversion cycle is extremely elevated at 4.1 million days, signaling severe working-capital inefficiency relative to peers and constraining reinvestment capacity.

Net debt to EBITDA of 1.2x is unfavorable for a company with weak profitability, because peers with stronger earnings can support similar leverage more safely.

Operating and gross margin data are unavailable, but the absence of demonstrated margin durability leaves CNSP structurally behind peers with proven scale economics.

Opportunities

If management converts its strong liquidity into clinical or commercial execution, CNSP could narrow the gap with peers that currently benefit from better operating leverage.

A zero debt-to-equity profile gives the company flexibility to fund development without immediate dilution pressure, unlike more levered peers facing tighter financing constraints.

Any improvement in working-capital discipline would have outsized impact because the current cash conversion profile is far weaker than that of typical listed peers.

Threats

Persistent negative ROIC increases the risk that peers with positive returns will compound faster, widening the competitive gap over a 2–5 year horizon.

Extremely poor cash conversion efficiency raises the likelihood of recurring financing needs, which can leave CNSP disadvantaged versus peers with self-funding operations.

If operating losses continue, the company’s current liquidity cushion may erode quickly, while stronger peers preserve strategic flexibility and market credibility.

Limited evidence of durable margins or segment strength makes CNSP vulnerable to peers with clearer product differentiation and more stable demand profiles.

Overall Score

CNSP’s peer positioning is weak overall because severe capital inefficiency and negative returns outweigh its relatively strong liquidity and low explicit leverage.